ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2017
Reply to E. Ritchie et al.
Aaron N Winn, Nancy L Keating, Stacie B Dusetzina
Abstract readLetterComment
In one paragraphArticle in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
3 authors.
Aaron N WinnAaron N. Winn, University of North Carolina at Chapel Hill, Chapel Hill, NC; Nancy L. Keating, Harvard Medical School and Brigham and Women's Hospital, Boston, MA; and Stacie B. Dusetzina, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, and Cecil G. Sheps Center for Health Services Research, Chapel Hill, NC.
Nancy L KeatingAaron N. Winn, University of North Carolina at Chapel Hill, Chapel Hill, NC; Nancy L. Keating, Harvard Medical School and Brigham and Women's Hospital, Boston, MA; and Stacie B. Dusetzina, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, and Cecil G. Sheps Center for Health Services Research, Chapel Hill, NC.
Stacie B DusetzinaAaron N. Winn, University of North Carolina at Chapel Hill, Chapel Hill, NC; Nancy L. Keating, Harvard Medical School and Brigham and Women's Hospital, Boston, MA; and Stacie B. Dusetzina, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, and Cecil G. Sheps Center for Health Services Research, Chapel Hill, NC.
Funding
North Carolina Translational & Clinical Sciences Institute (NC TraCS)UL1TR001111 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, CAREY, TIMOTHY S · 2013 to 2017
$43.9MBehavioral Economics and Improving Chemotherapy Decisions for Advanced CancerK24CA181510 · NCI · HARVARD MEDICAL SCHOOL · PI KEATING, NANCY L · 2014 to 2018
$867kNCATS NIH HHS UL1 TR001111NCI NIH HHS K24 CA181510
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Cost SharingLeukemia, Myelogenous, Chronic, BCR-ABL PositiveCognitionHumansMedicareProtein-Tyrosine KinasesUnited StatesProtein-Tyrosine Kinases
What OpenQuestion holds
Textmetadata
Read underepoch 390